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Impaired glucose tolerance (IGT) serves as a marker for 
the state of insulin resistance and predicts both large- 
and small-vessel vascular complications, independent of 
a patient’s progression to diabetes. Patients with IGT 
are at significantly increased risk for death and morbid­
ity due to myocardial infarction, stroke, and large- 
vessel occlusive disease. IGT is more predictive of 
cardiovascular morbidity than impaired fasting glucose, 
probably because it is a better surrogate for the state of 
insulin resistance. IGT is also independently associated 
with traditional microvascular complications o f diabe­
tes, including retinopathy, renal disease, and polyneu­
ropathy, which are the topics of this review. Inhibition 
of nitric oxide-mediated vasodilation, endothelial in­
jury due to increased release of free fatty acids and 
adipocytokines from adipocytes, and direct metabolic 
injury of endothelial and end-organ cells contribute to 
vascular complications. Early detection of IGT allows 
intensive diet and exercise modification, which has 
proven significantly more effective than drug therapy in 
normalizing postprandial glucose and inhibiting pro­
gression to diabetes. To what degree intervention will 
limit recognized complications is not known. Diabetes 
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Ten percent of Americans will develop type 2 diabetes during their lifetime. However, >20% will develop a more modest defect in glucose metabolism, designated impaired glucose toler­ance (IGT). IGT, defined as a serum glucose concentration 
between 140 and 199 mg/dl 2-h after a 75-g glucose load, 
reflects hepatic gluconeogenesis and slower uptake of 
glucose from blood into skeletal muscle and adipose tissue 
following a meal. Thus, an oral glucose tolerance test 
(OGTT) is a more sensitive measure of early abnormalities 
in glucose regulation than fasting plasma glucose or
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HbAlc. A developing literature links IGT to complications 
that traditionally are attributed to diabetes. These compli­
cations include both macrovascular (myocardial infarction 
and stroke) and microvascular (retinopathy, and mi­
croalbuminuria, polyneuropathy) disease. Vascular endo­
thelial and end-organ damage associated with IGT occurs 
due to a combination of transient hyperglycemia and 
lipotoxicity itself, as well as resulting from insulin resis­
tance and compensatory hyperinsulinemia,
This review discusses IGT and its natural history and 
examines the clinical consequences and pathogenesis of 
metabolic and vascular damage associated with IGT. We 
searched MEDLINE for English-language articles pub­
lished from 1966 through June 2003 about IGT, postpran­
dial hyperglycemia, and early diabetes in relationship to 
health effects and complications. Reference lists from 
retrieved articles were examined for additional pertinent 
articles or sources. The authors reviewed references 
jointly and placed emphasis on prospective study data 
where available.
Compared with age-matched normoglycemic control 
subjects, patients with IGT are at greater risk for death 
from all causes (1,2) and have a two- to fivefold increased 
incidence of new-onset. cardiovascular ischemia, fatal and 
total myocardial infarction, and stroke, independent of 
progression to diabetes (2,3). These macrovascular com­
plications of IGT have been extensively reviewed else­
where. This review will focus on the emerging recognition 
of IGT as a cause for microvascular complications: periph­
er l neuropathy, retinopathy, and microalbuminuria, 
Recognition and natural history o f IGT. Among rou­
tine tests of glucose metabolism, the 2-h OGTT most 
closely reflects postprandial glucose disposal. Patients fast 
overnight, then have blood drawn for a serum glucose 
immediately before and 2 h following an oral load of 75 g 
of dextrose. Under current. American Diabetes Association 
(ADA) criteria (Table 1), IGT corresponds to a 2-h serum 
glucose level between 140 and 199 mg/dl, while diabetes is 
defined as a 2-h value >200 mg/dl (4). The 1997 ADA 
criteria also established a range of fasting plasma glucose 
(110-125 mg/dl) meant, to correspond with IGT, desig­
nated impaired fasting glucose (IFG). However, numerous 
studies indicate that OGTT is more sensitive in detecting 
early glucose dysregulation than fasting plasma glucose. 
This disparity in sensitivity is particularly acute in younger 
patients: 23 of 112 obese adolescents (21%) had IGT, while 
only one had IFG (5).
A recent screening study in an unselected population
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TABLE 1








Normal <109 <139 NA
IFG 110-125 NA NA
IGT NA 140-199 NA
Diabetes >126 >200 Variable
IFG is preferred to  IGT by the ADA because of its greater conve­
nience, bu t IFG and IGT are regarded as equivalent. The ADA rec­
omm ends against use of IIbAu, as a  diagnostic tes t for diabetes. 
IIbAu , threshold for diabetes is variable, bu t typically betw een 6.1 
and 7.0%. No IIbAu. values are recognized as equivalent to  IGT or 
IFG.
found the prevalence of IGT to be 11.2% for ages 50-59 
years, peaking at 14.2% for ages 60-75, and declining in 
individuals older than 75 (6). Investigations of the natural 
history of IGT reveal a dynamic and reversible state. In a 
study of 200 adults >70 years old in Finland, one-third 
progressed from normoglycemia to IGT. Of IGT patients in 
this cohort, one-third reverted to normal glucose tolerance 
and one-fifth progressed to diabetes. Almost one-fifth of 
those with baseline diabetes reverted to IGT (7). The 
Diabetes Prevention Program (DPP) randomized 3,244 
patients with IGT to treatment with placebo, the biguanide 
antihyperglycemic agent metformin, or intensive diet and 
exercise counseling. Nearly 30% of 1,082 subjects receiving 
placebo progressed from IGT to diabetes >3 years, but 
during this same period 25% reverted to postprandial 
normoglycemia (8). Overall, most patients progress 
toward greater glycemic dysregulation, but this progress 
appears to be slow. In the DPP, mean fasting plasma 
glucose among placebo subjects rose from 107 to 112 
mg/dl over the average 3-year follow-up (8). Unmonitored 
patients probably experience many years of occult insulin 
resistance and postprandial hyperglycemia before devel­
oping typical symptoms of diabetes.
IGT is a surrogate for, and largely a consequence of, two 
intertwined and self-reinforcing processes that are inti­
mately associated with obesity and drive prediabetic hy­
perglycemia: insulin resistance and dyslipidemia (9). In 
obesity, as skeletal muscle loses sensitivity to insulin, 
more glucose is taken up by adipocytes, both stimulating 
production and release of free fatty acids (FFAs) and 
triglycerides and increasing adiposity. Elevated circulating 
FFAs in turn promote hyperglycemia by stimulating 
hepatic gluconeogenesis while inhibiting insulin-mediated 
glucose uptake and storage as glycogen.
Microvascular complications o f IGT: neuropathy, ret­
inopathy, and renal microproteinuria. Neuropathy is a 
common complication of diabetes occurring over time in 
more than half of patients with type 2 diabetes. Nerve 
conduction studies demonstrate that neuropathy is al­
ready present in 10-18% of patients at the time of diabetes 
diagnosis (10), suggesting that peripheral nerve injury 
occurs at early stages of disease and with milder glycemic 
dysregulation. The concept that neuropathy is an early 
clinical sign of diabetes was proposed >40 years ago, and 
most studies report an association between IGT and 
neuropathy. Prospective screening of patients with other­
wise “idiopathic” neuropathy using 2-h OGTT shows that, 
using the 1997 ADA criteria (11,12), 30-50% of these
patients have IGT, a significantly higher prevalence than 
seen in the age-matched general population (6). Similarly, 
a cross-sectional study using a combination of physical 
examination, focused history, and vibration threshold 
measurements found neuropathy in 26% of 279 patients 
with diabetes, 11.2% of 89 patients with IGT, and only 3.9% 
of 577 age-matched normal control subjects (13).
Most patients with IGT and associated neuropathy have 
a symmetric, distal sensory polyneuropathy with promi­
nent neuropathic pain (11,12). In the largest prospective 
series, 81% of neuropathy patients with IGT had exclu­
sively sensory complaints, and 92% recognized neuro­
pathic pain as a dominant symptom of their neuropathy 
(11). IGT neuropathy is phenotypically similar to early 
diabetic neuropathy, which also causes sensory symp­
toms, including pain, and autonomic dysfunction. In a 
survey of 669 patients with early diabetic neuropathy, 
sensory symptoms were present in >60%, impotence in 
nearly 40%, and other autonomic involvement in 33%, but 
evidence of motor involvement in only 12% (14). These 
clinical findings suggest prominent early involvement of 
the small unmyelinated nerve fibers that carry pain, tem­
perature, and autonomic signals. Direct quantitation of 
unmyelinated intraepidermal nerve fibers from skin biop­
sies shows similar fiber loss and altered morphology in 
patients with neuropathy associated with IGT and early 
diabetes (15).
Autonomic dysfunction, particularly erectile dysfunc­
tion and altered cardiac vagal response, are common early 
features of neuropathic injury in diabetes (16). Work with 
IGT patients also suggests prevalent vagal dysautonomia: 
separate studies have found abnormal heart rate recovery 
following exercise, blunted R-R interval variability to deep 
breathing, and reduced expiration to inspiration ratio (all 
measures of vagal dysautonomia) in a greater fraction of 
IGT patients than age-matched normoglycemic control 
subjects (17).
There is accumulating evidence that IGT is also associ­
ated with both renal and retinal injury. As with neuropa­
thy, a significant number of patients have nephropathy or 
retinopathy at the time of diabetes diagnosis (18,19), 
suggesting that these complications occur early in glu­
cose dysregulation. Multiple studies document an in­
creased prevalence of microalbuminuria in patients with 
IGT. Microalbuminuria, defined as a urine albumin-to- 
creatinine ratio of 30-299, is predictive of progression to 
frank proteinuria and is associated with cardiovascular 
mortality (20). Among >5,000 Maoria and European sub­
jects, microalbuminuria was found in 21% of those with 
diabetes and 16% of those with IGT, but only 4% of 
normoglycemic individuals (21). A very large population- 
based study in China performed OGTT in 4,000 patients 
with elevated postprandial glucose selected from 
>100,000 subjects. The rate of albumin excretion was 
significantly higher among IGT subjects compared with 
the nondiabetic control group (7.2 ± 5.7 vs. 4.5 ± 2.8) (22). 
Similar data are available for several other etlmic groups 
(23).
Clinical studies on retinopathy by multiple investigators 
have documented reduced visual acuity and contrast sen­
sitivity in subjects with IGT (24,25). Reduced acuity was 
observed in the Rancho Bernardo study despite a very low
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incidence of frank retinopathy (24). Independent studies 
have noted an approximate fourfold increase in the prev­
alence of retinopathy among Pima Indians with IGT com­
pared with age-matched control subjects (2:3). In the 
Western Samoa survey, 10% of IGT subjects had retinopa­
thy as compared with 17% of those with newly diagnosed 
diabetes and 45% of known diabetic subjects. Collectively, 
the data suggest that the first stage of retinal injury occurs 
during IGT. Indeed, metaanalysis suggests that risk for 
retinopathy or nephropathy begins to increase with a 2-h 
glucose of 9.0 mmol/1, which is in the lower half of the IGT 
range (2:3).
Pathogenesis of IGT complications: general consider­
ations. Direct metabolic injury, changes in vascular reac­
tivity, and accumulating endothelial injury each play a role 
in the pathogenesis of complications observed in patients 
with IGT. However, the relative contributions of each of 
these mechanisms is probably different for each compli­
cation. For instance, direct tissue ischemia caused by a 
failure of reactive vasodilation is arguably more important 
in driving small vessel complications, while inflammatory 
atherogenesis and defects of thrombolysis allow clot for­
mation and potentiate large-vessel complications, such as 
myocardial infarction and stroke. Insulin resistance, FFAs, 
and inflammatory cytokines released from adipocytes ap­
pear more important than hyperglycemia in causing 
chronic endothelial atherogenesis and thrombus forma­
tion. This may explain why insulin resistance is associated 
with complications, especially myocardial infarction, in 
patients who are still normoglycemic (26). It is less clear 
that insulin resistance is associated with microvascular 
complications in the absence of hyperglycemia, suggesting 
that elevated blood glucose plays a more important role in 
reducing small-vessel vasoreactivity. Finally, direct meta­
bolic tissue injury caused by hyperglycemia may be more 
important to “microvascular” complications, especially 
neuropathy. Significant controversies remain regarding 
the relative contributions of direct hyperglycemic injury 
and effects of insulin resistance, hyperinsulinemia, and 
hyperlipidemia. Each of these factor’s is discussed in turn. 
Hyperglycemia inhibits nitric oxide-m ediated vasodi­
lation. Vascular endothlial dysfunction is a pivotal feature 
of all IGT complications, and it develops in large part as a
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FIG. 1. Disruption of vascular NO signaling and direct 
metabolic injury contribute to IGT complications. NO syn­
thesized by eNOS mediates large- and small-vessel vasodi­
lation and promotes endothelial thrombolysis. Transient or 
sustained hyperglycemia depletes NADPH and increases 
formation of ROS. ROS directly damage endothelial and 
other target organ cells and alter utilization of NO from 
vasoregulatory tasks to detoxification of ROS. AGEs in­
crease ROS formation and cause direct metabolic injury. 
These synergistic insults promote small-tissue ischemia, 
large-vessel atherogenesis and thrombogenesis, and con­
tribute to complications in IGT.
consequence of acquired defects of nitric oxide (NO) 
signaling (Fig. 1). In endothelial smooth muscle cells, NO 
plays at least two critical and competing roles: vasodila- 
tory signaling and detoxification of reactive oxygen spe­
cies (ROS) that might otherwise cause oxidative tissue 
injury. NO is synthesized by NO synthase (NOS) in vascu­
lar endothelial cells in response to insulin and other 
stimuli, including acetylcholine, bradykinin, and mechan­
ical shear stress. Once generated, NO diffuses locally to 
cause arterial vasodilation with a half-life of 3-20 s. 
Blunting of vasorelaxation and increased large-vessel 
blood flow in response to methacholine or hyperemia in 
patients with insulin resistance indicates an early partial 
failure of this NO-dependent system (27,28). This blunted 
vasoreactivity contributes to increased hypertension in 
patients with IGT (28). Local NO also inhibits endothelial 
atherosclerosis and platelet aggregation. However NO 
necessary to perform these vasoregulatory tasks is de­
pleted by endothelial free radicals. NO reacts with and 
detoxifies endothelial ROS. This detoxification consumes 
NO, so large amounts of ROS induced by hyperglycemia 
serve as a sink for NO, making less NO available for 
vasodilation.
Hyperglycemia generates toxic ROS and drives a multi­
factorial depletion of NO. Hyperglycemia leads to activa­
tion of the enzyme aldose reductase, which converts 
excess glucose to sorbitol, which in turn is metabolized by 
sorbitol dehydrogenase to fructose (polyol pathway) (29). 
Glucose, and especially sorbitol and fructose, reacts non- 
enzymatically with proteins, lipids, and nucleic acids to 
produce advanced glycation end products (AGEs), which 
in turn induce ROS generation (30). Endothelial ROS 
formation is also increased in hyperglycemia by peroxida­
tion of more abundant glucose and LDLs and by dysregu- 
lation of transition metals that serve as catalysts for 
auto-oxidation (31). Finally, ischemia itself accelerates 
ROS formation by decreasing mitochondrial efficiency and 
by reperfusion injury. The result is local endothelial dam­
age by ROS and depletion of NO, impairing vasodilation.
These mechanisms appear particularly important for 
small arterioles, where failure of vasodilation may result in 
direct tissue ischemia. Drags that decrease ROS, including 
ROS scavengers (a-lipoic acid, glutathione, vitamin E),
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FIG. 2. Adipocyte lipolysis, release of FFAs, and changes in 
adipocytokines in response in states of insulin resistance and 
obesity contribute to both acute changes in vasoreactivity 
and chronic endothelial injury. Increased circulating FFAs 
reinforce insulin resistance and increase gluconeogenesis in 
the liver, accelerating hyperglycemia and feeding into the 
hyperglycemic effects described in Fig. 1. Fatty acid peroxi- 
daton directly increases ROS, and FFAs contribute to endo­
thelial injury. Insulin resistance increases adipocyte release 
of tumor necrosis factor-ot (TNF-ot), which acts through the 
sphingolipid ceramide to damage endothelial cells. Adiponec- 
tin secretion is reduced, with inhibition of its vasoprotectve 
effect.
lipid-lowering agents, and transition metal chelators (des­
feroxamine, a-lipoic acid) all slow 01* reverse peripheral 
nerve injury in animal models (31). However, there is good 
evidence for rapid vasoregulatory effects of transient 
hyperglycemia across a range of vessel calibers. IGT 
patients have reduced cutaneous vasodilation in response 
to acetylcholine (32). Moreover, Kawa.no et al. (33) found 
that oral glucose loading transiently reduced endothelial- 
dependent brachial artery vasodilation and that it was 
accompanied by a significant increase in circulating oxy­
gen-derived free radicals. Significant transient vasodila- 
tory blunting occurred in normal control subjects as well 
as those with IGT 01* diabetes. These results strengthen the 
concept of endothelial injury as a dynamic process, accu­
mulating over years of intermittent hyperglycemic insult. 
Insulin resistance. Insulin resistance and compensatory 
hyperinsulinemia are intimately linked to the metabolic 
syndrome, a combination of abdominal obesity, hyperten­
sion, and dyslipidemia that is associated with increased 
vascular disease. Epidemiologic studies indicate that vas­
cular complications are more frequent in insulin-resistant 
patients even before development of hyperglycemia. (34). 
Similarly, in normoglycemic and normotensive subjects 
with a family history of diabetes, systemic insulin resis­
tance correlates with blunted large-vessel NO-dependent 
vasoreactivity. This effect occurs independent of hypergly­
cemia. (27,32).
Two recent studies suggest mechanisms whereby insu­
lin resistance may disrupt insulin regulation of endothelial 
NOS (eNOS) activity. In a. recent cross-sectional study of 
volunteers without diabetes (35), degree of insulin resis­
tance was significantly correlated with increased plasma 
expression of asymmetric dimethylarginine, an endoge­
nous NOS inhibitor, a risk factor for myocardial infarction. 
Treatment with rosiglitazone, an insulin-sensitizing agent, 
reduced asymmetric dimethylarginine levels, suggesting 
that insulin may directly regulate levels of this enzyme 
(35). Insulin binds the insulin receptor on the surface of 
endothelial cells to induce NO synthesis by eNOS. Activa­
tion by insulin of the serine/threonine protein kinase Akt 
increases phosphorylation of NOS in rat cardiac muscle,
increasing its activity (36). This stimulatory phosphoryla­
tion may be blocked by 0-glycosylation of eNOS at the 
Aktrspecific phosphorylation site as a consequence of 
hyperglycemia, and increased hexosamine generation (37). 
However, the phosphorylation state of eNOS in the setting 
of insulin resistance has not been reported, and other 
mechanisms for insulin regulation of eNOS activity may 
also exist, Interestingly, disruption of vascular NO signal­
ing in mice by inhibiting eNOS activity, 01* in eNOS 
knockout mice, leads to a. state of insulin resistance (38). 
These findings point to a complicated regulatory relation­
ship between insulin and NO in vascular tissue.
Endothelial proliferation is also a consequence of dis­
proportionate mitogenic signaling associated with insulin 
resistance. In obese rats, insulin resistance selectively 
inhibits insulin signaling through the phosphatidylinositol 
3-kinase Akt pathway, but signaling through the mitogen- 
activated protein kinase pathways remains permissive. As 
hyperinsulinemia develops, mitogen-activated protein ki­
nase signaling increases, promoting vascular proliferation
(39). Finally, important NO-independent. mechanisms of 
vascular injury have been identified. Hyperglycemia in­
creases signaling through the protein kinase C-diacylglyc- 
erol signal transduction pathway. In animal and human 
studies, protein kinase C alters blood flow and plays a role 
in damage of both small and large vessels, including 
basement membrane thickening and neovascularization
(40).
FFAs and adipocytokines induce endothelial injury.
As described above, obesity and insulin resistance pro­
mote production and release of FFAs from adipocytes, 
while FFAs increase insulin resistance and sustain hyper­
glycemia, Independent of these efFects, accumulating evi­
dence indicates that excessive FFAs induce both acute 
changes in vasoregulation and promote chronic endothe­
lial injury (Fig. 2). FFAs potently inhibit eNOS activation in 
cultured endothelial cells (41), and reduce acetylcholine- 
dependent vascular reactivity in human subjects, implicat­
ing NO-mediated signaling (42). Generation of ROS by 
increased lipid peroxidation has been implicated in these 
effects, and inhibitors of this process slow progression of
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experimental hyperglycemic neuropathy. Insulin resis­
tance and hyperlipidemia coexist in most IGT patients. 
Comparison of vascular reactivity in patients with hyper­
triglyceridemia stratified as either highly or only slightly 
insulin resistant suggest that insulin resistance is a more 
potent inhibitor of NO-dependent. vasoreactivity than hy­
perlipidemia (43). Lipotoxicity probably also contibutes to 
chronic endothelial inflammatory injury. In healthy volun­
teers, feeding with lipids (50 g/rrr) resulted in a sustained 
postprandial increase in circulating neutrophils and the 
proinflammatory cytokine interleukin (IL)-8 (44).
Hormones secreted from adipocytes, termed “adipocy- 
tokines,” play an important role in regulating food related 
behavior, metabolism, and vascular function. Altered se­
cretion of two adipocytokines, tumor necrosis factor- 
alpha (TNF-a) and adiponectin, in obesity and IGT con­
tributes to endothelial injury and promotes early vascular 
complications. TNF-a is a pro-inflammatory adipokine that 
acts through the sphingolipid second messenger ceramide. 
Ceramide has been shown to induce oxidative stress and 
apoptosis in endothelial cells and is associated with accel­
erated atherosclerosis in experimental models (45). TNF-a 
activation of ceramide also accelerates insulin resistance, 
probably by inhibiting insulin receptor coupling to IRS-1. 
There are mixed data regarding whether circulating TNF-a 
is increased in obesity and IGT. However, acute glucose 
infusion results in TNF-a release from adipocytes that is 
more profound and durable in IGT patients than in nor­
moglycemic control subjects (46). Thus IGT patients may 
be at greater risk for TNF-a-mediated vascular injury.
Adiponectin is a novel adipocyte-derived peptide that 
has several salutory vascular effects: it inhibits vascular 
smooth muscle proliferation and appears to inhibit mac­
rophage-mediated endothelial injury. Adiponectin secre­
tion is reduced in obesity and hyperglycemic states. 
Reduced adiponectin is independently associated with 
reduced forearm blood flow, and may be permissive for 
arteriolar endothelial injury and atherosclerosis (47). 
Overall it is clear that increased adiposity and FFAs induce 
endothelial vascular dysfunction independent of their pro­
motion of hyperglycemia in IGT.
Other metabolic effects o f hyperglycemia. Although 
the above discussion has focused on vascular dysregula­
tion and damage, it is clear that direct toxic and metabolic 
damage from hyperglycemia and hyperlipidemia play a 
role in development of IGT complications, especially neu­
ropathy. Because of their long axons and high-energy 
requirements, peripheral neurons may be uniquely suscep­
tible to the direct metabolic effects of hyperglycemia (48). 
Both ROS and AGEs are directly neurotoxic (29). AGEs 
promote inappropriate covalent cross-links between pro­
teins. This process is accelerated in response to hypergly­
cemia and greater polyol pathway flux (30). AGEs cause 
neuronal-specific injury by inhibiting axonal transport, 
resulting in axonal degeneration that is proportional to the 
length of the axon (48). AGE-induced protein crosslinking 
is also implicated in sclerosis of renal glomeruli, capillary 
basement membrane thickening, and small-vessel athero­
sclerosis and occlusion (30). Defects in mitochondrial 
electron transport leading to increased superoxide gener­
ation has been suggested as a key contributor to metabolic 
irg'ury mediated by the polyol, protein kinase C, AGE, and
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hexosamine pathways (49). Mitochondrial dysfunction 
might account for persistent injury that occurs during 
periods of normoglycemia and contributes to genetic 
differences in susceptibility to hyperglycemic complica­
tions (49).
Treatment and areas for future study. Results from the 
DPP and similar large prospective studies in Finland and 
China make it clear that aggressive modification of diet 
and exercise can prevent or slow the progression from IGT 
to diabetes (8). In the DPP, diet and exercise modification 
was significantly more effective in diabetes risk reduction 
than pharmacological glucose reduction with metformin 
(58 vs. 31% reduction compared with placebo) (8). Diet 
and exercise was also more effective than metformin in 
returning IGT subjects to a normal glucose tolerance. DPP 
participants are being followed prospectively to examine 
changes in blood pressure, lipid profiles, atherosclerosis, 
and cardiovascular disease. In a separate study of IGT 
patients, 6 months of diet and exercise modification mod­
eled on the DPP improved brachial artery reactivity, but 
not microvascular reactivity, suggesting that microvascu­
lar changes may be more difficult, to reverse (50).
The results of the DPP and similar studies should 
transform the standard of care for hyperglycemic screen­
ing and treatment of patients with IGT. The 2-h glucose 
tolerance test has been criticized as less convenient and 
more variable than fasting plasma glucose. However, the 
epidemiological results highlighted in this review strongly 
argue that OGTT is a more sensitive marker of transient 
hyperglycemia and insulin resistance than fasting plasma 
glucose and is better correlated with risk for large-vessel 
atherogenic complications (5). Identification of IGT 
should prompt the clinician to screen for hypertension, 
dyslipidemia, and possibly cardiovascular disease. IGT 
patients should be referred to a nutritionist for coordi­
nated counseling on modification of exercise and diet with 
the goal of losing 5-7% of body weight and increasing 
moderate aerobic exercise to 150 min weekly (the DPP 
goals) (8). Future studies are needed to more clearly 
define the natural history of progressive glucose intoler­
ance; examine direct metabolic effects of hyperglycemia, 
insulin resistance, and hyperinsulinemia; and examine 
additive effects of lifestyle modification and pharmaco­
therapy on macrovascular and microvascular complica­
tions of IGT.
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